Literature DB >> 15550140

Elevated MIA levels in the serum of pregnant women and of children.

A K Bosserhoff1, H Küster, R Hein.   

Abstract

Recent studies have shown that the protein MIA (melanoma inhibitory activity) is a potent serum marker for malignant melanoma. MIA is expressed in chondrocytes at high levels, and might potentially be elevated during periods of growth in childhood. Therefore, we evaluated MIA serum levels in pregnant women and in growing children. We found that no significant enhancement of MIA serum levels was apparent until 38 weeks of pregnancy. Starting at 38 weeks, a significant increase was noted. The study further revealed that children and teenagers also have increased MIA serum levels. However, from the age of 17 years MIA serum levels are not different from those in healthy adults. In summary, MIA can be used as a serum marker for melanoma in adults starting at the age of 17 years. In pregnant women (> 38th week), children, and teenagers MIA should not be used in serum diagnostics for malignant melanoma until larger studies have been performed to generate cut-off levels for each group.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15550140     DOI: 10.1111/j.1365-2230.2004.01623.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  7 in total

Review 1.  [Melanoma and pregnancy].

Authors:  C Erfurt-Berge; E Kaempgen
Journal:  Hautarzt       Date:  2010-12       Impact factor: 0.751

2.  The expression of melanoma inhibitory activity on mast cells in child patients with cutaneous mastocytosis.

Authors:  Yuko Ehara; Yuichi Yoshida; Makoto Tahira; Osamu Yamamoto
Journal:  Yonago Acta Med       Date:  2014-10-15       Impact factor: 1.641

3.  Metabolomic identification of diagnostic serum-based biomarkers for advanced stage melanoma.

Authors:  A W L Bayci; D A Baker; A E Somerset; O Turkoglu; Z Hothem; R E Callahan; R Mandal; B Han; T Bjorndahl; D Wishart; R Bahado-Singh; S F Graham; R Keidan
Journal:  Metabolomics       Date:  2018-08-03       Impact factor: 4.290

Review 4.  Diagnostic and prognostic biomarkers in melanoma.

Authors:  David Weinstein; Jennifer Leininger; Carl Hamby; Bijan Safai
Journal:  J Clin Aesthet Dermatol       Date:  2014-06

Review 5.  Emerging Biomarkers in Cutaneous Melanoma.

Authors:  Anna Eisenstein; Estela Chen Gonzalez; Rekha Raghunathan; Xixi Xu; Muzhou Wu; Emily O McLean; Jean McGee; Byungwoo Ryu; Rhoda M Alani
Journal:  Mol Diagn Ther       Date:  2018-04       Impact factor: 4.074

6.  A synopsis of serum biomarkers in cutaneous melanoma patients.

Authors:  Pierre Vereecken; Frank Cornelis; Nicolas Van Baren; Valérie Vandersleyen; Jean-François Baurain
Journal:  Dermatol Res Pract       Date:  2012-01-12

Review 7.  Evaluating biomarkers in melanoma.

Authors:  Panagiotis Karagiannis; Matthew Fittall; Sophia N Karagiannis
Journal:  Front Oncol       Date:  2015-01-23       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.